InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today ...

InMode halts control sale after rejecting final bids including Centroid Sale process shelved as InMode board rejects all final bids, including from Centroid ...

InMode Ltd. is rated a Strong Buy due to its robust balance sheet, proprietary technology, and international growth. Learn more about INMD stock here.

InMode has a strong competitive position in the rapidly growing global aesthetic market with its innovative products and technology. The company has achieved impressive financial performance with ...

YOKNEAM, Israel, Feb. 2, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies ("InMode" or the "Company"), today issued the following statement ...

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable ...

Interested investors are welcome to contact their BTIG salesperson and schedule a meeting. For more information about the event, visit InMode's investor relations site here.

InMode Ltd INMD reported Q2 sales of $136.1 million, an increase of 20% Y/Y, beating the consensus of $132 million and slightly above the preliminary numbers. Adjusted EPS reached $0.72, compared to ...

On April 12, 2023 at 14:48:47 ET an unusually large $189.99K block of Put contracts in Inmode (INMD) was bought, with a strike price of $40.00 / share, expiring in 37 days (on May 19, 2023). Fintel ...